Skip to main content
Premium Trial:

Request an Annual Quote

Navigenics Cuts Price of Screening Service 60 Percent

NEW YORK (GenomeWeb News) – Consumer genomics firm Navigenics has cut the price of its comprehensive genetic screening service by 60 percent, from $2,500 to $999, the firm announced on its blog, The Navigator.

A thousand dollars buys customers a year subscription to Navigenics' Health Compass testing services, which includes genetic risk data for 28 diseases and conditions; an hour-long session with a genetic counselor; and updates to risk scores as new gene associations and diseases are added to the service.

Navigenics launched Health Compass in 2007. The company conducts its genetic risk scans using Affymetrix arrays, and earlier this year it took over ownership of Affy's CLIA lab.

Also earlier this year, Navigenics launched a pared down version of its service, Annual Insight, that costs $499 and provides individuals with information about their genetic predisposition for 10 common health conditions, including breast, colon, and prostate cancer, celiac disease, Crohn's disease, type 2 diabetes, glaucoma, heart attack, macular degeneration, and osteoarthritis. The company markets this version of its service to doctors, aiming to drive the integration of genomic information into people's yearly medical checkups.

Navigenics is not the only the firm to drop the price of its DTC genomics service offering. Last year, one of its competitors, 23andMe, lowered the cost of its service from $999 to $399, citing technological advancements in the Illumina platform.

Further competitive pressure has come from the launch this week of Pathway Genomics, a San Diego-based DTC genetic testing firm that is offering genotyping and analysis for disease risk and heredity for under $250.


A more detailed version of this article is available on GenomeWeb Daily News sister publication Pharmacogenomics Reporter.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.